Stay in the loop! Subscribe to our newsletter and gain access to exclusive insights, trends, and news from the world of business and leadership. Don’t miss out!
Shares of Japan's Eisai fell sharply by 11% on Monday, marking their biggest one-day decline in three years.
Shares of Japan’s Eisai fell sharply by 11% on Monday, marking their biggest one-day decline in three years. This was due to the European Union’s regulator rejecting the company’s Leqembi treatment for early Alzheimer’s disease.
The EU drugs regulator recently concluded that the risks of serious brain swelling associated with Leqembi outweigh its small impact on slowing cognitive decline. The rejection was a significant setback for Eisai, which had widely anticipated EU approval.
Eisai, along with its partner Biogen, announced plans to seek a re-examination of the EU’s decision but did not specify the additional information they would provide to the regulator.
The rejection surprised investors and analysts, leading to a substantial drop in Eisai’s share price. Jefferies analyst Stephen Barker described the EU’s decision as a “big negative surprise,” highlighting concerns that this rejection could damage Leqembi’s reputation and sales potential in other markets, including the U.S. and Japan.
Barker further noted that removing European sales projections for Leqembi could result in a 20% reduction in overall sales estimates and decrease Eisai shares’ “fair value” by approximately 1,000 yen each.
In morning trading in Tokyo, Eisai’s shares dropped to 5,890 yen, the company’s largest one-day fall since July 2021. This followed a 7% decline in Biogen’s shares in U.S. trading on Friday.
Leqembi, also known as lecanemab, is currently approved in the U.S., China, Hong Kong, Israel, Japan, and South Korea. It would have been the first drug in Europe to treat Alzheimer’s disease rather than merely address its symptoms.
The EU’s rejection challenges Eisai and Biogen as they navigate regulatory hurdles and market perceptions in the global rollout of their Alzheimer’s treatment.
Championing Excellence and Female Leadership in Engineering Sheeba Benny, a trailblazer in the field of electrical
How a 21-Year-Old Turned a Conservatory Start-Up into a $650,000 Business At just 21 years old,
With the global speaking industry valued at over $2 billion and growing rapidly, companies and event
In the world of technology-driven transformation, few leaders stand out as much as Senthil Babu, CEO
How DDSports and DeLuca Designs Business Academy are Revolutionizing Markets and Inspiring a New Generation of
